ERBB2 and neoplasm: Initially proposed by June and Gill in 2017, CAR-M constructs targeting CD19, mesothelin, and HER2 have demonstrated robust phagocytic and cytotoxic activity against antigen-expressing tumour cells [278, 290, 327].